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Abstract Biopotential is an electrochemical potential that has been shown to correlate well with the
coagulation zone size during cardiac RF catheter ablation. We designed an in vivo experiment to test
the hypothesis that a similar correlation exists during hepatic RF ablation. We created coagulation zones,
in vivo, in porcine liver, with 17 gauge needle electrodes, using RF ablation (n = 56). The power was
set constant at 30 W, controlled by impedance, and applied for 60, 120 or 180 s. We measured the
biopotential between the electrode and the ground pad with low-pass filtering. The diameter and volume
of the coagulation zone were measured and correlated with the change in biopotential between the
beginning and end of each ablation procedure. Moderate correlation between biopotential change and
both coagulation zone volume (R2 = 0.43) and diameter (R2 = 0.31) was observed. The time constant
of the biopotential change was not significantly different from the time constant of the ablation zone
diameter (36.6 s, p = 0.93); the biopotential may, therefore, predict the time course of the ablation zone
diameter. The biopotential can potentially be used for intraprocedural monitoring of the progression of
the thermal damage zone. It may also allow termination of the procedure, if it can be confirmed that the
biopotential reliably correlates with the cessation of ablation zone expansion.
© 2012 Sharif University of Technology. Production and hosting by Elsevier B.V.
Open access under CC BY license.1. Introduction
Primary liver cancer remains one of the most widespread
cancers worldwide, with approximately 500,000 new cases per
year [1]. Additionally, colorectal cancer is one of the most
commonly diagnosedmalignancies in theUnited States,with an
estimated 150,000 new cases and 57,000 deaths annually [2]. A
significant number of these deaths are as a result of metastatic
liver tumors, which occur in nearly half of all colorectal cancer
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Open access under CC BY license.cases [3]. The standard curative treatment for both types of
hepatic cancer is surgical resection, with 5 year survival rates of
25%–50% [3–6]. However, only 10%–20% of cases are amenable
to resection. This may be due to anatomic considerations (such
as bilobar disease or proximity to vasculature), limited hepatic
reserve or co-morbid disease creating high surgical risk [6,7].
Over the past ten years, a number of technologies have
emerged in the treatment of unresectable liver cancer, includ-
ing cryoablation, microwave ablation, laser ablation and ra-
diofrequency (RF) ablation [8]. Currently, RF ablation is the
ablative modality used most widely, worldwide. In RF abla-
tion, an electrode (typically 14–17 gauge) is first inserted into
a liver tumor percutaneously, laparoscopically or during open
surgery. Alternating electric current in the radiofrequency spec-
trum (typically 450–500 kHz) is then applied to the electrode,
resulting in resistive heating of the tissue around the electrode.
Over the course of a typical procedure, a roughly spherical area
of tissue between 3 and 6 cm in diameter – depending on elec-
trode type – is heated above 50 °C, resulting in coagulation
necrosis. In addition to the management of hepatic cancer, RF
ablation is increasingly being used to treat tumors in other soft
organ tissue, including kidney, breast and lung, as well as bone
marrow [9,10].
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in determining the extent of thermal tissue damage during
the course of each procedure. The primary real-time imaging
modality used during RF procedures is intraoperative ultra-
sound (IOUS). During the monitoring of RF ablations with IOUS,
a hyperechoic region forms in the area around the electrode,
due tomicrobubbles generated during tissue boiling [11]. How-
ever, prior studies have demonstrated that this hyperechoic re-
gion does not accurately demarcate the zone of thermal coagu-
lation [12]. This inability to accurately monitor the progress of
the ablation in real-time reduces the efficacy of the treatment,
lengthens procedural time, and necessitates lengthy (and often
inconclusive) follow-up imaging [13]. Computerized tomogra-
phy (or CT) can be used to accurately monitor the ablation zone
during percutaneous RF ablation (the CT equipment is too con-
straining to be used during open surgical procedures). However,
the time necessary for this imaging modality precludes it from
practical use as a real time monitor of ablation zone formation.
Previous studies have demonstrated that a DC (direct cur-
rent) electrochemical potential (hereafter, ‘biopotential’) de-
velops between the active electrode and a reference electrode
during cardiac catheter RF ablation ofmyocardial tissue [14,15].
It has been hypothesized that this biopotential is a result of free
radicals and electrolytes released during tissue injury [14]. The
magnitude of this biopotential correlated stronglywith final ab-
lation zone volume in prior studies [14,15]. We hypothesized
that a measurable biopotential would similarly develop during
RF ablation of liver tissue, and possibly allow real-time estima-
tion of ablation zone dimensions.
2. Materials and methods
2.1. RF generator
We used a commercially available Valleylab 200 W Cool Tip
generator and a Valleylab 17 gauge Cool Tip needle electrode
to create all ablation zones. The stainless steel electrode
had an exposed tip length of 3 cm. Cooling water was not
circulated through the electrodes during the experiments,
because it interfered with the formation of the biopotential
signal in preliminary trials. Possibly, the region of sub-
lethal temperatures surrounding the cooled ablation electrode
hindered development of the potential. RF energy (460 kHz)
was applied in a unipolar mode between the needle electrode
and a large tin defibrillation dispersive electrode in contact
with the animal’s skin. The generator was operated, using an
impedance controlled algorithm, in which a constant power is
applied to the tissue until the measured impedance increases
a predetermined amount over the baseline impedance (due
to tissue vaporization near the electrode) [16]. At this point,
the generator stops delivering energy for 15 s to allow the
impedance to decline before reapplying power.
2.2. Biopotential
The biopotential signals developed during ablation were
measured and recorded using a digital oscilloscope (Agilent
54621A) with 10 : 1 probes. We used a passive low-pass RC
filter with a corner frequency of 7 Hz to isolate the biopotential
signal from the applied RF power signal. Figure 1 is the
schematic of the measurement circuit.
The value of the biopotential was determined by subtracting
the starting potential from the lowest potential reached during
each trial, as shown below in Figure 2. Note that the startingFigure 1: A low pass filter (RLPF = 976 k and CLPF = 22 nF) between the
electrodes and the oscilloscope removes the high frequency RF signal from the
biopotential.
Figure 2: Biopotential waveform from a typical in vivo trial. The maximum
voltage differential for each trial was used for correlation with ablation zone
dimensions. The discontinuities (arrows) result from RF power being turned
on/off, due to the impedance control algorithm used for power control. The
dashed line represents the exponential approximation of thiswaveform [v(t) =
A exp(−t/τ)− (A− v(0))]. For this particular trial, the values of A and τ were
0.077 and 38.3 s, respectively.
potential is larger than any cell membrane potential and is
therefore not likely due to living tissue. Rather, it is likely due to
the offset potential that develops when electrodes of dissimilar
metals are placed into an electrolytic solution [17].
2.3. Animals
Pre-approval for all animal experiments was obtained from
the Institutional Animal Care and Use Committee, University
of Wisconsin, Madison. Six domestic swine (approximately
15–35 kg) were used in this study. The animals were
first injected intramuscularly with a narcotic preanesthetic,
Telazol R⃝, then anesthetized with inhaled halothane and
intubated via a tracheostomy. The abdominal wall was then
incised to access the liver. At the conclusion of each experiment,
the animals were euthanized by intracardial injection of
potassium chloride.
2.4. Procedure
To create each ablation, the needle electrode was inserted
into the liver at a suitable location, so that the entire exposed
portion of the electrode was inside the tissue. 30 W of power
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ablation zone volume and themagnitude of the biopotential signal (R2 = 0.43).
were then applied to the electrode for 60, 120 or 180 s; the time
of energy delivery was randomized to create ablation zones of
different sizes. The biopotential signals observed during each
ablation were recorded and saved for later analysis. After the
required number of ablations was created, the animal was
sacrificed and the ablated lobes of liver resected. The liver was
then placed in 10% formalin for fixation.
2.5. Measurements
The fixed liver tissue was sliced perpendicularly to the
direction of the electrode insertion and images of the slices
taken with a digital camera. The software ImageJ (http://
rsb.info.nih.gov/ij/) was used to measure the area, perimeter
and diameter of the resulting ablation zones. Boundaries of
tissue necrosis were determined by visual inspection. Ablation
zone volume was calculated by multiplying the ablation zone
area by the slice thickness, and summing for all slices. The
diameter was measured as the value of the minor axis of the
fitted ellipse for each slice of the ablation zone. Slices, where
the ablation zone extended to the surface of the lobe, were
excluded from the diameter measurement because of their
nonsymmetry. The minor axis was chosen to account for any
nonorthogonality in the tissue slicing. The diameter reported in
the results below is themaximum value of all the slices for each
ablation zone. Pearson’s correlation coefficient (R2)was used to
analyze correlations between ablation zone dimensions and the
biopotential for each trial.
We fit an exponential function by minimizing the square of
error to the relationship between the ablation zone volume (V )
versus time, and the diameter (d) versus time: e.g. d(t) = A(1−
exp(−t/τ)), with amplitude A and time constant τ . Similarly,
we fitted an exponential function to each of the biopotential
time courses (see Figure 2). We used the Student’s t-test to
determine whether there is a difference between the time
constants of ablation zone growth (volume and diameter) and
biopotential change.
3. Results
A total of 56 RF ablations were performed and analyzed in
this study. Figure 3 shows the moderate correlation (R2 =
0.43) between the biopotential change and the corresponding
ablation zone volume.
Figure 4 shows the relationship betweenmaximum ablation
zone diameter and the biopotential. The correlation between
this parameter and the biopotential change was not as strong
(R2 = 0.31).Figure 4: Correlation between the postfixation maximum ablation zone
diameter and the magnitude of the biopotential signal was weaker than that
for the volume (R2 = 0.31).
Figure 5: The diameter data were fitted to an exponential curve of the form
f (t) = A(1 − exp(−t/τ)). The values of A and τ were 0.962 and 35.8 s,
respectively.
Figure 6: The volume data were fitted to an exponential curve of the form
f (t) = A(1 − exp(−t/τ)). The values of A and τ were 2.09 and 91.7 s,
respectively.
While we expect some difference in correlation between the
biopotential and either the diameter or volume, from our data,
it is unclear which of these two parameters shows the better
correlation.
The time constants for ablation zone volume (V ) and
diameter (d)were 91.7 s and 35.8 s, respectively (see Figures 5
and 6). The time constant for biopotential change was 36.6 ±
37.7 s, and was significantly different from the time constant
for ablation zone volume (p < 0.001), but not the diameter
(p = 0.93).
During several of the trials (n = 26), there were rapid
voltage changes or ‘‘spikes’’ in the biopotential waveform.
Figure 7 shows an example of this phenomenon.
These trials were not included in the results, because
we believed the voltage spikes caused the magnitude of the
measured potential to be overstated.
1514 D.J. Schutt et al. / Scientia Iranica, Transactions D: Computer Science & Engineering and Electrical Engineering 18 (2011) 1511–1515Figure 7: An example of the nonlinear ‘‘spike’’ inmagnitude of the biopotential
signal recorded during some of the trials.
4. Discussion
Currently, a significant limitation of RF ablation is the in-
ability to accurately image the ablation zone during treatment.
While IOUS is the current standard for imaging open RF abla-
tions, it tends to overestimate the size of the ablation zone. We
postulated that biopotential changes could help predict the size
and growth of the ablation zone more accurately. We demon-
strate that biopotential increased in all cases during the course
of treatment.We further demonstrate that increasing biopoten-
tial was associated with an increase in ablation zone dimen-
sions. From a clinical standpoint, however, the correlation is not
strong enough to suggest clinical use at this point. Though the
biopotential signal was not helpful in assessing the size of the
ablation zone, itmay assist in determining the duration of treat-
ment. During longer trials, i.e. 3min, themagnitude of the signal
stopped increasing near the end of the ablation (see Figure 2).
This could allow us to determine when the ablation zone stops
increasing in size, indicating that the ablation procedure can be
terminated, since the continued application of RF energy will
not result in further growth of the ablation zone.
Currently, constant ablation time is typically used for each
procedure (12–45 min, depending on device); e.g. for the
Valleylab Cool-tip ablation system, the procedural time of 12
min is based on a study performed by Goldberg et al. [18].
However, electrical and thermal tissue properties (especially
blood perfusion) differ from organ to organ, from healthy
to tumor tissue, and even from location to location within
each organ. Therefore, since the thermodynamic conditions
are different at each ablation site, the required application
time is also likely different for each procedure. By monitoring
the biopotential, we may be able to determine when each
ablation zone has reached its maximum size and terminate the
procedure, thus using optimal treatment time. To investigate
this possibility, we compared the time constants of ablation
zone growth and biopotential change. While the time constant
of the ablation zone volumewasmuch longer (92 s, p < 0.001),
the ablation zone diameter had a time constant (35.8 s) close to
that of the biopotential (36.6 s, p = 0.93). However, since we
do not have data on ablation zone growth for each trial, but only
an estimate based on cumulative data from all trials, further
experiments are necessary,which acquire data on ablation zone
growth versus time during each trial (either by imaging or
multiple temperature measurements).4.1. Limitations
As mentioned above, previous studies have shown a
strong correlation between the magnitude of the biopotential
observed during the cardiac catheter RF ablation of the
myocardium and ablation zone dimensions [14,15]. In the
present study, analysis of the relationship between the
biopotential and final ablation zone dimensions, using porcine
liver tissue, was less conclusive. There were several differences
in our experimental methodology that may account for the
weaker observed correlation. The RF generator used in our
study did not automatically ramp up the power applied to the
tissue at the beginning of each trial; the power was manually
adjusted to a final value of 30W over a period of approximately
5 s. Irregularities in this adjustment may have caused some
or all of the waveform ‘‘spikes’’ noted in the previous section
(Figure 7), again possibly as a result of polarization of the
electrodes during the initial application of RF energy. Any
nonlinear effectsmayhave beenmore pronounced in this study,
due to the difference in materials between cardiac electrodes
(platinum) and those used in this study (stainless steel).
Additionally, our measurements of ablation zone volume and
diameter may have been less accurate due to the small volume
of coagulated tissue formed during ablations using a single
needle electrode (without cooling). Additional experiments,
where ablation zones of similar size as clinically seen (3–6 cm
diameter) are required to further determine the utility of the
biopotential in monitoring ablation zone formation.
5. Conclusion
One current shortcoming of tumor radiofrequency ablation
procedures is insufficient intraprocedural information about
ablation zone size. The biopotential investigated in this study
may provide this missing information. Furthermore, it may
allow the termination of radiofrequency ablation procedures
when the ablation zone has reached its maximum size, possibly
reducing currently lengthy treatment times.
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